COMPANY
NImmune Biopharma
Timeline
- Trial start Phase 1: Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis source ↗
- Trial start Phase 2: Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease source ↗
- Trial start Phase 1: Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers source ↗
- Trial start Phase 2: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease source ↗
- Trial start Phase 2: Efficacy and Safety of Oral BT-11 in Ulcerative Colitis source ↗
- Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03870334 | Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease | Phase 2 | Terminated | May 5, 2021 | Aug 26, 2022 (actual) |
| NCT03861143 | Efficacy and Safety of Oral BT-11 in Ulcerative Colitis | Phase 2 | Completed | Aug 14, 2019 | Dec 10, 2020 (actual) |
| NCT05019950 | Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers | Phase 1 | Completed | Oct 28, 2021 | Apr 28, 2022 (actual) |
| NCT05057273 | Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease | Phase 2 | Withdrawn | 2021-11 | 2022-02 (estimated) |
| NCT04835168 | Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis | Phase 1 | Withdrawn | Jan 30, 2022 | Apr 30, 2022 (estimated) |
| NCT03860571 | Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers | Phase 1 | Completed | Jul 6, 2018 | Sep 24, 2018 (actual) |